Clinical trials
Breast Cancer Risk clinical trials
Below are recruiting breast cancer risk clinical trials, each written for real people, not researchers. We’re tracking 740 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07381985Enrolling by invitation
Managing hereditary cancer risk in rural areas
This study tests a way to help people with inherited cancer gene mutations manage their health, especially if they live in rural areas. You join if you found out about the mutation more than a year ago.
Burlington, VermontAges 18 years+ - NCT04345081Recruiting
Compare two breast surgery skin-sparing methods and recovery
This trial compares two types of mastectomy (with skin and nipple options) and implant reconstruction to see which gives better cosmetic results, comfort, and satisfaction. You may help doctors learn which approach leads to a better quality of life after surgery.
BudapestAges 18–65 - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Phoenix, ArizonaAges 18 years+ - NCT07358806RecruitingPhase 1
Study of OCT-598 for advanced solid tumors
This trial tests a new drug called OCT-598, alone or with chemotherapy, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
Goyang-siAges 18 years+ - NCT07711847Recruiting
Prone positioning for faster breast radiation therapy
This trial tests a personalized prone-immobilization device for partial breast radiation after surgery. It aims to make treatment more comfortable and accurate for patients who have had breast-conserving surgery.
New York, New YorkAges 40 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Daphne, AlabamaAges 18 years+ - NCT06960720Recruiting
Weight lifting program for breast cancer fatigue
This trial tests whether a 3-month resistance exercise program (like lifting weights) can help reduce fatigue in women who have had breast cancer. You may be eligible if you were diagnosed with non-metastatic breast cancer 1-3 years ago and feel tired, even if only a little.
Morgantown, West VirginiaAges 18 years+ - NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT07220863Recruiting
Breast mapping test for finding suspicious spots
This trial tests a new Feminai device that maps breast tissue to find suspicious lumps. If you're coming for a routine mammogram or a biopsy, this could help improve detection.
Frisco, TexasAges 25–75 - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT06209099Recruiting
Organ preservation first for low-risk rectal cancer
This trial tests a strategy to avoid surgery by using watchful waiting after initial treatment for early-stage rectal cancer. It may help patients keep their rectum and avoid a permanent colostomy.
Beijing, Haidian DistrictAges 18–85 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05800574RecruitingPhase 2
Targeted neck radiation for p16-positive favorable throat cancer
This Phase 2 study tests whether a more precisely targeted radiation plan to the neck can work for people with p16-positive oropharynx cancer that is considered “favorable risk.” Doctors use special imaging to map where lymph nodes are likely involved, aiming to treat the right areas while avoiding unnecessary treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06722599Recruiting
Shorter chemo with targeted drugs for low-risk HER2 breast cancer
This trial tests whether a short course of chemo plus two targeted drugs (trastuzumab and pertuzumab) before surgery works well for people with early-stage, low-risk HER2-positive breast cancer. It may help reduce the need for stronger chemo later.
Beijing, Beijing MunicipalityAges Any age - NCT04170634Recruiting
CT scan study to assess bone strength in certain cancers
This study uses a CT scan to estimate how strong a cancer-affected bone area is, helping doctors evaluate fracture risk and bone management. It is aimed at adults with bone lesions from several common cancer types.
AngersAges 18 years+ - NCT07386444Recruiting
Breathing exercises for breast cancer patients on chemo
This trial tests whether special breathing exercises can help breast cancer patients feel better during chemotherapy. You would do simple, guided breathing workouts to strengthen your breathing muscles.
Columbus, OhioAges 18 years+ - NCT06804395Recruiting
Community cancer screening registry study
This study creates a registry to better understand and improve cancer screening for people at higher risk. By joining, you help researchers learn how to prevent and manage cancer in your community.
Totowa, New JerseyAges 18 years+ - NCT05006131Recruiting
Pancreatic cancer screening for people at higher risk
This study looks at how to screen the pancreas in people who are at increased risk for pancreatic cancer, using a set of risk guidelines. Screening may help find cancer (or early changes) sooner, when it may be easier to treat.
Boston, MassachusettsAges 18–90 - NCT06081244RecruitingPhase 3
Testing sacituzumab govitecan with or without pembrolizumab for early triple-negative breast cancer
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT07047495Recruiting
Personalized radiation therapy for early breast cancer
This trial is testing a way to personalize radiation therapy for people with early-stage breast cancer. It may help make treatment more precise and reduce side effects.
Milan, ItalyAges 18 years+ - NCT05852223RecruitingPhase 2
Pembrolizumab for high-risk thyroid cancer that cannot be fully removed
This study tests pembrolizumab (an immune therapy) in people with high-risk thyroid cancer that is hard to treat with surgery alone. It looks at whether this drug can reduce persistent or recurrent cancer after your planned treatment.
Pavia, LombardyAges 18 years+
Hear when a new Breast Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer risk?
- Yes. Clin2 currently lists 740 recruiting breast cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.